Author： Coiffier Bertrand
Publisher： Informa Healthcare
ISSN： 0735-7907
Source： Cancer Investigation, Vol.24, Iss.5, 2006-06, pp. : 548-552
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Hepatitis B virus (HBV) reactivation is a frequent complication in inactive HBV carriers at time of chemotherapy or following this chemotherapy. This complication appeared during or after chemotherapy and was not increased by the use of rituximab alone or combined with chemotherapy. This is a severe complication most frequently seen in lymphoma patients. Lamivudine have efficacy to treat the patients once the clinical disease is present. However, lamivudine prophylaxis beginning before chemotherapy and until at least 6 months after the end of chemotherapy is recommended for all HBV carriers. Hepatitis C virus is usually not associated with reactivation and prophylaxis should not be used.
Related content
Access to resources
Recommend
Molecular Medicine Reports, Vol. 9, Iss. 4, 2014-01 ,pp. :
By Simon Arne Besuden Mette Vezmar Sandra Hasan Carola Lampe Dagmar Kreutzberg Sigrid Glasmacher Axel Bode Udo Fleischhack Gudrun
Supportive Care in Cancer, Vol. 15, Iss. 2, 2007-02 ,pp. :